Google
FHTX — FOGHORN THERAPEUTICS INC (Healthcare >> Biotechnology)
FHTX FAQ
What is FHTX's ROE?
FOGHORN THERAPEUTICS INC reports a Return on Equity (ROE) of 98.58%.
What is FHTX's dividend yield?
FOGHORN THERAPEUTICS INC offers a dividend yield of 0.00%.
What is FHTX's Deepscope Quality Score?
Deepscope rates FHTX's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy FHTX?
Deepscope's AI Timing Score for FHTX is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does FHTX belong to?
FOGHORN THERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 3.64
Price
0.01
(0.28%)
Day Change
|
|
|---|
FHTX, ファンダメンタルスコアはnot good ( ファンダメンタル = 23) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROAが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
ROAの伸びが低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 69 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 3.64 |
| PBV / Sector |
-2.79 / 4.48
|
| Earning Per Share | -1.29 |
| PE / Sector |
N/A / 16.68
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
0.70 M
GREAT
|
| Average 1W Daily Value |
0.60 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
37% |
| ポイントになる統計 |
|
47% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-04 09:24:10 |
| Symbol | FHTX |
| Name | FOGHORN THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 58.71 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 213.13 / 8,483.11 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 99 Coolidge Avenue, Watertown, MA, United States, 02472
Phone: 617 586 3100
Website: https://foghorntx.com
Employees: 106
Sector: Healthcare >> Biotechnology
Description: Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
